Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 15, 2026, 6:37 AM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 217–240 of 464 matching trials from the live ClinicalTrials.gov search.

Filters: Intervention: Arm 1- Dose Expansion Clear all

Conditions: Solid Tumor
Interventions: JBZ-001; Drug
Lead sponsor: Jabez Bioscience, Inc; Industry
Eligibility: 18 Years and older
Enrollment: 25 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2028
U.S. locations: 2
States / cities: Columbus, Ohio • West Valley City, Utah

Conditions: Breast Cancer, Ovarian Cancer
Interventions: AZ2281 + Carboplatin; Drug
Lead sponsor: National Cancer Institute (NCI); NIH
Eligibility: 18 Years to 100 Years
Enrollment: 103 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2008 – 2019
U.S. locations: 1
States / cities: Bethesda, Maryland

Conditions: Non-small Cell Lung Cancer (NSCLC)
Interventions: S095018, S095024, S095029, S095018 Recommended Dose Expansion (RDE), S095024 RDE, S095029 RDE, Cemiplimab; Drug
Lead sponsor: Servier Bio-Innovation LLC; Industry
Eligibility: 18 Years and older
Enrollment: 102 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2027
U.S. locations: 3
States / cities: Detroit, Michigan • Canton, Ohio • Columbus, Ohio

Conditions: Advanced/Metastatic Solid Tumors
Interventions: ADG126 Mono, ADG126-anti PD1, ADG126-ADG106; Biological
Lead sponsor: Adagene Inc; Industry
Eligibility: 18 Years and older
Enrollment: 58 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2024
U.S. locations: 2
States / cities: Los Angeles, California • San Antonio, Texas

Conditions: Locally Advanced Solid Tumor, Metastatic Cancer, Non-small Cell Lung Cancer, Small Cell Lung Cancer, Mesothelioma, Melanoma, Head and Neck Cancer
Interventions: CTX-471, Pembrolizumab (KEYTRUDA®); Drug
Lead sponsor: Compass Therapeutics; Industry
Eligibility: 18 Years and older
Enrollment: 100 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2025
U.S. locations: 10
States / cities: Ocala, Florida • Port Saint Lucie, Florida • Boston, Massachusetts + 6 more

Conditions: Advanced Solid Tumors Cancer
Interventions: ABBV-428, Nivolumab; Drug
Lead sponsor: AbbVie; Industry
Eligibility: 18 Years to 99 Years
Enrollment: 61 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2016 – 2019
U.S. locations: 7
States / cities: Scottsdale, Arizona • Sacramento, California • Chicago, Illinois + 4 more

Conditions: Cancer, Hematologic Malignancies, Leukemia, Myeloid Leukemia
Interventions: Arm 1- Dose Escalation, Arm 2- Dose Expansion; Drug
Lead sponsor: Amgen; Industry
Eligibility: 18 Years and older
Enrollment: 35 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2011 – 2014
U.S. locations: 3
States / cities: Stony Brook, New York • Cleveland, Ohio • Houston, Texas

Conditions: Unresectable Metastatic Colorectal Cancer, Unresectable Locally Advanced Colorectal Cancer
Interventions: STC-1010 + IS regimen + SOC therapy; Biological
Lead sponsor: Brenus Pharma; Industry
Eligibility: 18 Years to 75 Years
Enrollment: 90 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2029
U.S. locations: 1
States / cities: Baltimore, Maryland

Conditions: Advanced Tumors
Interventions: CPI-100, Capecitabine; Drug
Lead sponsor: Coordination Pharmaceuticals, Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 36 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2022
U.S. locations: 3
States / cities: Grand Rapids, Michigan • Cleveland, Ohio • San Antonio, Texas

Conditions: Part 1：r/r B-cell Malignancies, Part 2：B-cell Malignancies
Interventions: Orelabrutinib (ICP-022); Drug
Lead sponsor: Beijing InnoCare Pharma Tech Co., Ltd.; Industry
Eligibility: 18 Years and older
Enrollment: 81 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2026
U.S. locations: 27
States / cities: Phoenix, Arizona • Anaheim, California • Los Angeles, California + 24 more

Conditions: Breast Cancer, Hormone Receptor-positive Breast Cancer, Hormone Receptor Positive HER-2 Negative Breast Cancer
Interventions: VS-6766, Abemaciclib, Fulvestrant; Drug
Lead sponsor: Adrienne G. Waks; Other
Eligibility: 18 Years and older
Enrollment: 63 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2028
U.S. locations: 3
States / cities: Boston, Massachusetts

Conditions: Neoplasms With Mesothelin Expression, Epithelioid Mesothelioma, Cholangiocarcinoma, Extrahepatic, Adenocarcinoma, Pancreatic
Interventions: LMB-100, Tofacitinib, Mesothelin Expression; Drug · Device
Lead sponsor: National Cancer Institute (NCI); NIH
Eligibility: 18 Years and older
Enrollment: 19 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2021
U.S. locations: 1
States / cities: Bethesda, Maryland

Conditions: Selected Advanced Solid Tumors
Interventions: MEDI5752, Pemetrexed, Carboplatin, Pembrolizumab, Paclitaxel or Nab-Paclitaxel; Biological · Drug
Lead sponsor: MedImmune LLC; Industry
Eligibility: 18 Years to 120 Years
Enrollment: 400 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2027
U.S. locations: 7
States / cities: Detroit, Michigan • New York, New York • Chapel Hill, North Carolina + 4 more

Conditions: Breast Neoplasms, Breast Cancer, Adenocarcinomas, Metastatic Solid Tumors Characterized by HER2/Neu Expression
Interventions: Adenoviral Transduced Autologous Human Epidermal Growth Factor Receptor (AdHER)2/neu Dendritic Cell (DC) Vaccine; Biological
Lead sponsor: National Cancer Institute (NCI); NIH
Eligibility: 18 Years and older
Enrollment: 33 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2013 – 2019
U.S. locations: 1
States / cities: Bethesda, Maryland

Conditions: Advanced Solid Tumor, Non Small Cell Lung Cancer, Head and Neck Squamous Cell Carcinoma (HNSCC), Nasopharyngeal Carcinoma (NPC)
Interventions: BGB-A445, tislelizumab; Drug
Lead sponsor: BeiGene; Industry
Eligibility: 18 Years and older
Enrollment: 204 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2025
U.S. locations: 3
States / cities: Los Angeles, California • San Diego, California • Pittsburgh, Pennsylvania

Conditions: Hematologic Neoplasms
Interventions: BAY1251152; Drug
Lead sponsor: Bayer; Industry
Eligibility: 18 Years and older
Enrollment: 21 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2016 – 2018
U.S. locations: 3
States / cities: New York, New York • The Bronx, New York • Nashville, Tennessee

Conditions: Bladder Cancer
Interventions: Durvalumab, Tremelimumab, Radiation Therapy; Drug · Radiation
Lead sponsor: Terence Friedlander, MD; Other
Eligibility: 18 Years and older
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2024
U.S. locations: 1
States / cities: San Francisco, California

Conditions: ALS (Amyotrophic Lateral Sclerosis)
Interventions: Autologous T-regulatory lymphocytes, Interleukin-2; Biological
Lead sponsor: The Methodist Hospital Research Institute; Other
Eligibility: 18 Years and older
Enrollment: 3 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2016 – 2018
U.S. locations: 1
States / cities: Houston, Texas

Conditions: Metastatic Castration-resistant Prostate Cancer, Metastatic Prostate Cancer
Interventions: BPX-601, Rimiducid; Biological · Drug
Lead sponsor: Regeneron Pharmaceuticals; Industry
Eligibility: 18 Years and older
Enrollment: 52 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2016 – 2023
U.S. locations: 13
States / cities: Tampa, Florida • Atlanta, Georgia • Chicago, Illinois + 9 more

Conditions: Advanced Malignant Solid Neoplasm, ALK Positive, Metastatic Pancreatic Adenocarcinoma, Stage III Pancreatic Cancer, Stage IV Pancreatic Cancer
Interventions: Ceritinib, Cisplatin, Gemcitabine Hydrochloride, Laboratory Biomarker Analysis, Paclitaxel Albumin-Stabilized Nanoparticle Formulation, Pharmacological Study; Drug · Other
Lead sponsor: Roswell Park Cancer Institute; Other
Eligibility: 18 Years and older
Enrollment: 38 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2015 – 2019
U.S. locations: 1
States / cities: Buffalo, New York

Conditions: X-Linked Retinitis Pigmentosa
Interventions: BIIB112; Biological
Lead sponsor: Biogen; Industry
Eligibility: 10 Years and older · Male only
Enrollment: 50 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2020
U.S. locations: 5
States / cities: Gainesville, Florida • Miami, Florida • Portland, Oregon + 2 more

Conditions: EGFR Mutant Advanced Non-small Cell Lung Cancer
Interventions: JIN-A02; Drug
Lead sponsor: J Ints Bio; Industry
Eligibility: 18 Years and older
Enrollment: 150 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2026
U.S. locations: 1
States / cities: Orange, California

Conditions: Acute Myeloid Leukemia (AML), Acute Myeloid Leukemia With FMS-like Tyrosine Kinase 3 (FLT3) Mutation / Internal Tandem Duplication (ITD)
Interventions: gilteritinib, fludarabine, cytarabine, granulocyte colony-stimulating factor (G-CSF); Drug
Lead sponsor: Astellas Pharma Global Development, Inc.; Industry
Eligibility: 6 Months to 21 Years
Enrollment: 9 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2025
U.S. locations: 1
States / cities: Memphis, Tennessee

Conditions: Solid Tumor, Adult
Interventions: DF9001, KEYTRUDA® (pembrolizumab); Drug
Lead sponsor: Dragonfly Therapeutics; Industry
Eligibility: 18 Years and older
Enrollment: 24 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2025
U.S. locations: 17
States / cities: Gilbert, Arizona • Phoenix, Arizona • Irvine, California + 14 more

Search by objective public record fields.

Trial to Evaluate the Safety & Tolerability of JBZ-001 in Pts With Advanced Solid and Hematological Malignancies

AZD2281 Plus Carboplatin to Treat Breast and Ovarian Cancer

Phase 1b/2 Platform Study of Select Immunotherapy Combinations in Participants With Advanced Non-small Cell Lung Cancer (NSCLC)

ADG126, ADG126 in Combination With Anti PD1 Antibody, and ADG126 in Combination With ADG106 in Advanced/Metastatic Solid Tumors

Study of CTX-471 as a Monotherapy or in Combination With Pembrolizumab in Patients Post PD-1/PD-L1 Inhibitors in Metastatic or Locally Advanced Malignancies

A Study of ABBV-428, an Immunotherapy, in Subjects With Advanced Solid Tumors

Study Evaluating Orally Administered AMG 900 in Adult Subjects With Acute Myeloid Leukemia

First-in-human Trial of STC-1010, an Immunotherapy, in Patients With Unresectable Locally Advanced or Metastatic Colorectal Cancer

Study of CPI-100 in Patients With Advanced Tumors

A Study of Tyrosine Kinase Inhibitor Orelabrutinib (ICP-022) in Patients With r/r B-Cell Malignancies

VS-6766+Abema+Fulv in Met HR+/HER- BC

Mesothelin-Targeted Immunotoxin LMB-100 in Combination With Tofacitinib in Persons With Previously Treated Pancreatic Adenocarcinoma, Cholangiocarcinoma and Other Mesothelin Expressing Solid Tumors

A Study to Evaluate MEDI5752 in Subjects With Advanced Solid Tumors

Ad/HER2/Neu Dendritic Cell Cancer Vaccine Testing

Safety and Preliminary Effectiveness of BGB-A445 in Combination With Tislelizumab in Participants With Advanced Solid Tumors

Phase I Trial of BAY1251152 for Advanced Blood Cancers

Radiation Therapy and Durvalumab, With or Without Tremelimumab, in Patients With Bladder Cancer

Ph1 T-Regulatory Cells in Amyotrophic Lateral Sclerosis

Safety and Activity Study of PSCA-Targeted CAR-T Cells (BPX-601) in Subjects With Selected Advanced Solid Tumors

Ceritinib and Combination Chemotherapy in Treating Patients With Advanced Solid Tumors or Locally Advanced or Metastatic Pancreatic Cancer

A Clinical Trial of Retinal Gene Therapy for X-linked Retinitis Pigmentosa Using BIIB112

A Phase 1/2 Study to Evaluate the Safety, Tolerability and PK of JIN-A02 in Patients With EGFR Mutant Advanced NSCLC

A Study of Gilteritinib (ASP2215) Combined With Chemotherapy in Children, Adolescents and Young Adults With FMS-like Tyrosine Kinase 3 (FLT3)/Internal Tandem Duplication (ITD) Positive Relapsed or Refractory Acute Myeloid Leukemia (AML)

Study of DF9001 in Patients With Advanced Solid Tumors